Aura Biosciences (AURA) said Monday that data from a completed phase 1 trial of bel-sar in patients with non-muscle-invasive bladder cancer demonstrated a "robust anti-tumor immune response."
The company said the trial enrolled 15 patients, with primary endpoints of evaluating the safety and feasibility of bel-sar alone in five patients and bel-sar with light activation in 10 patients.
Clinical complete responses were observed with a single, low dose of bel-sar in patients with intermediate and high-risk non-muscle-invasive bladder cancer, supporting bel-sar's potential as a new treatment instead of, or ahead of, the standard of care procedure, the company said.
Bel-sar was also well tolerated as drug-related grade 1 events were reported in less than 10% of the patients, the company said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。